Stay true to our original aspiration, pursue our dreams, move forward with one heart, and set sail toward a brighter future.

"The old gives way to the new, and each day brings fresh momentum"—the extraordinary and unforgettable year of 2016 has already passed, while the promising year of 2017 is now unfolding its grand chapter.

2017 On February 22, Jilin Boda Weiye Pharmaceutical Co., Ltd. held its annual work conference titled "Stay True to Our Original Aspiration, Pursue Our Dreams, Move Forward Together, and Set Sail for Success" at the Peninsula Hui Conference Hall in Liaoyuan City. Over 220 attendees participated in the meeting, including company shareholders, representatives from代理商 (agents), leaders from relevant organizations, and all employees of the company.

     The conference featured General Manager Xie Wenbo's work report titled "Staying True to Our Original Aspiration, Pursuing Dreams, Moving Forward Together, and Setting Sail." The curtain rises in China The report provides a comprehensive, objective, and impartial summary of the company's development in 2016, while also outlining the company's strategic vision and key objectives for 2017.

General Manager Xie Wenbo noted in the report that, under the firm guidance of the company's board of directors and with the concerted efforts of the management team and all employees, Bodaweiyue has successfully emerged from the "black hole" and is now embracing a brighter future, witnessing significant progress across all aspects of the business.

First, the company has achieved new advancements in innovation. In 2016, Boda Weiye was recognized with prestigious honors such as the Provincial-level Technology Innovation Pilot Center, Provincial-level Technology Innovation Platform, and Municipal-level Science and Technology Innovation Center.

Second, the product sales and academic promotion efforts have yielded remarkable results. In 2016, sales of the Polyprize Zinc product established a robust market distribution network. By adopting a marketing approach that prioritizes "disease-centric academic marketing" and "physician-led service marketing," the company has developed a comprehensive "academic marketing + service marketing" philosophy, ensuring full implementation of the "12357" marketing objectives set at the beginning of the year.

The Central Marketing Department has achieved remarkable academic promotion results, hosting 4 national-level conferences, 2 regional-level meetings, and 14 in-house promotional sessions. Additionally, the department has filed 3 national patent applications, laying a solid academic foundation for boosting the direct sales volume of Pupurei Zinc Granules.

The two injectable products—sodium ferulate and mannan peptide—adopted a strategic approach focused on targeted market development, precise investor recruitment and selection, and timely bidding processes. As a result, they have successfully secured investment in 8 provinces and garnered preliminary interest from another 7 provinces, achieving market coverage in 15 provinces and attaining a nationwide market penetration rate of 60%.

Third, the research and development of new products has achieved steady growth. Jilin Province Boda Weiye Pharmaceutical Research Co., Ltd., a subsidiary of the company, has transitioned to independent operation, taking full responsibility for its own profits and losses. As a result, its R&D efforts have shifted from solely internal innovation toward a more scientific approach that includes external collaborations, technology transfers, and partnerships with other organizations.

2017 This year is a critical one for the company’s survival and growth. We must build our brand through academic excellence and achieve comprehensive market coverage through strategic planning. By carefully crafting a precise roadmap for the Ruilai Sheng brand, we aim to ensure that the brand’s strategic achievements during this planning phase are promoted promptly and effectively. Meanwhile, Jilin Boda Weiye Pharmaceutical Research Co., Ltd., while continuing to meet the company’s future R&D needs, will actively embrace market-driven mechanisms to expand its efforts in external technology transfer and technical service offerings.

Chairman Duan Chengjun, in his inspiring speech, noted that 2017 was "a year when new opportunities quietly arrived, new challenges emerged head-on, fresh ideas elevated our development, and groundbreaking actions forged our brilliance" for Jilin Province Bodaweiye Pharmaceutical Co., Ltd.

Bo Da Wei Ye is advancing on a glorious journey, Let us remain confident, seize the opportunities, and move forward with determination to create a bright and promising future filled with great achievements.

At the meeting, the company recognized and rewarded the outstanding teams and individuals of 2016.

After the meeting Employees from relevant literary and artistic groups and companies within the province Performed wonderful and elegant cultural and artistic programs.